Tesamorelin vs CJC-1295
GHRH Analog · GHRH Analog
Here is how these two compounds compare, based on published research, not marketing claims.
Tesamorelin
The only GHRH analog with current FDA approval; specifically indicated for visceral fat reduction in HIV-associated lipodystrophy.
CJC-1295
A GHRH analog with a DAC modification that sustains GH release for days; research-stage, not FDA-approved.
Tesamorelin
110 studies
37 human trials
FDA-Approved
CJC-1295
27 studies
2 human trials
Not FDA-Approved
What it does
Tesamorelin
Currently the only FDA-approved GHRH analog. Marketed as Egrifta to reduce visceral fat in HIV patients whose antiretroviral medications cause abnormal fat redistribution. A small chemical modification at the front of the peptide protects it from being broken down, which is what gives the FDA-label dose its sustained growth hormone response rather than the minutes-long signal native GHRH would produce.
CJC-1295
Stretches a growth hormone signal that normally lasts minutes into one that lasts days. A small chemistry change attaches the molecule to albumin, a protein already circulating in the blood, which protects it from being broken down. In the published research, that translates to a half-life of roughly six to eight days, compared with minutes for the body's native GHRH.
How it works
Tesamorelin
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) with a trans-3-hexenoic acid modification that improves stability. It binds GHRH receptors on pituitary somatotrophs, stimulating pulsatile growth hormone release that follows the body's natural rhythm. The downstream GH elevation reduces visceral adipose tissue through increased lipolysis and hepatic fat oxidation.
CJC-1295
A modified version of the body's natural growth hormone signal. The modification makes it resist breakdown, so it stays active longer in the bloodstream.
How often
Tesamorelin
FDA labeling for Egrifta specifies daily subcutaneous injection for the HIV-associated lipodystrophy indication. The compound is not FDA-approved for any indication outside HIV-associated visceral fat reduction.
CJC-1295
In Phase I/II trials, CJC-1295 with DAC was given as a subcutaneous injection once or twice per week. The DAC modification (drug affinity complex) extends the active window to several days, which is what allows the once-or-twice-weekly schedule rather than daily injection.
How strong
Tesamorelin
FDA-approved with completed Phase III trials demonstrating visceral fat reduction in the HIV-associated lipodystrophy population. The Phase III STARS trial showed significant reduction in trunk fat. GH and IGF-1 elevation documented across multiple studies. The only GHRH analog that achieved and maintained FDA approval through a complete regulatory process.
CJC-1295
Stronger and more sustained. A bigger growth hormone pulse that lasts longer.
Main tradeoff
Tesamorelin
FDA-approved but only for HIV-associated lipodystrophy, a narrow indication. Off-label use for body composition or anti-aging in non-HIV populations is common in clinical practice but lacks the Phase III data that supports the approved use. The compound is more expensive than non-FDA-approved GHRH analogs (sermorelin, CJC-1295) because it carries the regulatory and manufacturing costs of an FDA-approved pharmaceutical product.
CJC-1295
Less pulsatile than the body's natural rhythm. Side effects, if they happen, stick around longer because the drug stays active longer.
Best for
Tesamorelin
- Adults with diagnosed HIV-associated lipodystrophy under physician supervision
- Research comparing FDA-approved versus non-approved GHRH analogs
- Clinical contexts where FDA-approved GH-stimulating therapy is required by protocol
CJC-1295
- People who want fewer injections per week
- People who've plateaued on Sermorelin
- Anyone planning to stack with Ipamorelin (a popular combination because the two work through different receptors and amplify each other)
How to choose
A good fit for Tesamorelin
- Clinical treatment for HIV-associated lipodystrophy under physician supervision
- Research contexts where FDA-approved status and completed Phase III data are required
- Research comparing FDA-approved versus non-approved GHRH analogs
A good fit for CJC-1295
- Research on extended-duration GHRH receptor activation (multi-day pharmacokinetics)
- Research protocols requiring once-weekly rather than daily injection
- Research comparing GHRH receptor signaling across different analog modifications
Consider both across time
Tesamorelin and CJC-1295 both activate the GHRH receptor on pituitary somatotrophs to stimulate growth hormone release. The key distinctions are regulatory status, pharmacokinetics, and cost. Tesamorelin has FDA approval with Phase III trial data for one specific indication (HIV-associated visceral fat). CJC-1295 has extended multi-day activity from the DAC modification but never completed Phase III trials. Off-label use of tesamorelin for body composition in non-HIV populations is common in clinical practice but lacks the Phase III data that supports the approved use.
Dosing should be determined by a qualified physician who can evaluate individual circumstances. PSI does not provide personalized dosing guidance.
Official dosing references
- DailyMed(NIH drug labels)
- ClinicalTrials.gov
- PubMed
For readers who want the biology: here is the pathway each compound uses to signal the body. This section is optional. The comparison above covers the practical differences.
▶See the biology
- GHRH Receptor
- GHRH Receptor activates Pituitary Somatotrophs
- Pituitary Somatotrophs stimulates Pulsatile GH Release
- Pulsatile GH Release connects to IGF-1 Elevation; Growth Hormone Release connects to IGF-1 Elevation
- Pulsatile GH Release drives Visceral Fat Lipolysis
- Visceral Fat Lipolysis connects to Visceral Adipose Reduction
- GHRH Receptor activates GHRH Signaling
- GHRH Signaling connects to Anterior Pituitary
- Anterior Pituitary connects to Growth Hormone Release
Tesamorelin activates the GHRH receptor on pituitary somatotrophs with a trans-3-hexenoic acid modification for improved stability.
CJC-1295 mimics GHRH to tell the pituitary gland to release growth hormone; the DAC modification extends activity from minutes to days.
Research Evidence
Tesamorelin has the strongest regulatory evidence in the GHRH analog class: completed Phase III trials (STARS) demonstrating statistically significant visceral fat reduction, FDA approval as Egrifta, and ongoing post-market surveillance data. CJC-1295 has Phase I/II pharmacokinetic data establishing sustained GH release and IGF-1 elevation from the DAC modification, but development was halted before Phase III completion. The evidence gap between the two compounds is structural: tesamorelin passed the FDA regulatory bar; CJC-1295 did not reach it.
- 1.
For an evidence-based GHRH analog with regulatory approval, tesamorelin is the only option.
- 2.
For broader GH optimization protocols in peptide therapy, CJC-1295 is more commonly used off-label.
- 3.
For visceral fat reduction with clinical support, tesamorelin has specific trial data.
- 4.
For cost and accessibility in non-medical contexts, CJC-1295 is more widely available through compounding.
Key Limitations
- •Tesamorelin's approval is specific to HIV lipodystrophy, off-label use lacks regulatory backing.
- •CJC-1295 has very little formal clinical data despite widespread use.
- •Cost and insurance coverage differ significantly.
- •No head-to-head trial exists.
Community Discussion
PSI monitors discussions across peptide research and biohacking communities. These are reported experiences, not clinical evidence.
Tesamorelin
"Tesamorelin is the only FDA-approved peptide that actually reduces belly fat"
Supported by published data
"It is better than regular GH for fat loss because it does not cause insulin resistance"
Plausible but unproven
"Biohackers are using it off-label for general fat loss"
Anecdotal only
CJC-1295
"CJC-1295 with DAC gives you sustained growth hormone elevation for days"
Supported by published data
"Stacking CJC-1295 with ipamorelin is the gold standard for GH optimization"
Plausible but unproven
"It made me retain water and feel bloated"
Supported by published data
Safety Comparison
Tesamorelin has a well-characterized safety profile from Phase III trials and post-market surveillance: injection site reactions, peripheral edema, and arthralgia are the most commonly reported adverse events. FDA labeling includes a carcinogenicity warning based on long-term animal studies. CJC-1295 has limited safety data from Phase I/II trials: injection site reactions, water retention, and numbness. Neither compound's long-term safety for off-label body composition use in non-HIV populations is well-characterized.
Tesamorelin
Well-characterized from Phase III trials. Side effects include injection site reactions, joint pain, and peripheral edema. Contraindicated in certain conditions.
CJC-1295
Limited but generally favorable. Common side effects include water retention, numbness, and injection site reactions.
What the Research Suggests
Tesamorelin is the regulatory gold standard among GHRH analogs. CJC-1295 is the accessibility alternative. If evidence matters, tesamorelin wins. If the question is practical availability for GH optimization, CJC-1295 is more commonly used.